Effects of macrophage colony-stimulating factor (M-CSF) on the mobilization of peripheral blood stem cells.

Abstract:

:We studied the effects of human urinary macrophage colony-stimulating factor (huM-CSF) on the mobilization of peripheral blood stem cells (PBSC) following cytotoxic chemotherapy in 6 patients with acute leukemia. After complete remission (CR) was achieved, two courses of consolidation chemotherapy consisting of an intermediate dose of cytosine arabinoside were administered to the patients. During a recovery phase after each course of consolidation chemotherapy, two successive cycles of leukapheresis were performed every other day. M-CSF was administered intravenously at a dose of 8 x 10(6) U/day during a recovery phase after the second course of consolidation chemotherapy (cytotoxic plus M-CSF mobilization). There was no significant difference in white blood cell (WBC) or platelet recovery between the first and second cycles, regardless of the administration of M-CSF. Furthermore, between cytotoxic and cytotoxic/M-CSF mobilization, significant differences were not observed in the harvest of mononuclear cells (average 1.43 x 10(8)/kg vs 1.62 x 10(8)/kg), granulocyte/macrophage progenitor cells (CFU-GM) (1.82 x 10(4)/kg vs 3.07 x 10(4)/kg) or erythroid progenitor cells (BFU-E) (2.86 x 10(4)/kg vs 2.66 x 10(4)/kg). Thus M-CSF is not effective for expanding a pool of circulating hematopoietic stem cells when administered at a conventional dose during hematologic recovery following chemotherapy.

journal_name

Bone Marrow Transplant

authors

Eto T,Takamatsu Y,Harada M,Harada N,Akashi K,Teshima T,Inaba S,Okamura T,Niho Y

subject

Has Abstract

pub_date

1994-02-01 00:00:00

pages

125-9

issue

2

eissn

0268-3369

issn

1476-5365

journal_volume

13

pub_type

杂志文章
  • Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation.

    abstract::Posttransplant cyclophosphamide (PTCy:100 mg/kg) has been increasingly used in allogeneic hematopoietic stem cell transplantation, however, few studies compared different doses of PTCy. We conducted two consecutive prospective multicenter phase II studies to evaluate the safety and efficacy of 80 mg/kg of PTCy in 137 ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-01065-0

    authors: Sugita J,Kamimura T,Ishikawa T,Ota S,Eto T,Kuroha T,Miyazaki Y,Kumagai H,Matsuo K,Akashi K,Taniguchi S,Harada M,Teshima T

    更新日期:2020-09-24 00:00:00

  • Evaluation of pretransplant influenza vaccination in hematopoietic SCT: a randomized prospective study.

    abstract::Pretransplant influenza vaccination of the donor or allogeneic hematopoietic SCT (HSCT) candidate was evaluated in a randomized study. One hundred and twenty-two HSCT recipients and their donors were assigned to three randomization groups: no pretransplant vaccination (n=38), donor pretransplant vaccination (n=44) or ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1038/bmt.2015.47

    authors: Ambati A,Boas LS,Ljungman P,Testa L,de Oliveira JF,Aoun M,Colturato V,Maeurer M,Machado CM

    更新日期:2015-06-01 00:00:00

  • Administration and pharmacokinetics of high-dose cyclophosphamide with hemodialysis support for allogeneic bone marrow transplantation in acute leukemia and end-stage renal disease.

    abstract::We report a patient with pre-existing end-stage renal disease (ESRD) who underwent successful matched related donor allogeneic bone marrow transplantation for AML in second complete remission (CR2) using conditioning with high-dose cyclophosphamide (CY, 60 mg/kg/day x 2) and TBI (165 cGy twice daily x 4 days). The tim...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701646

    authors: Perry JJ,Fleming RA,Rocco MV,Petros WP,Bleyer AJ,Radford JE Jr,Powell BL,Hurd DD

    更新日期:1999-04-01 00:00:00

  • Minimal residual disease testing after stem cell transplantation for multiple myeloma.

    abstract::Increased use of novel agents and autologous stem cell transplantation has led to a significant improvement in PFS and overall survival in patients with multiple myeloma. Despite improved treatment strategies, most patients eventually relapse due to persistent low levels of disease in the bone marrow. Increasingly sen...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/bmt.2015.164

    authors: Sherrod AM,Hari P,Mosse CA,Walker RC,Cornell RF

    更新日期:2016-01-01 00:00:00

  • Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease.

    abstract::We investigated the effect of 0.05% topical cyclosporine (Cys) on the ocular surface and tear functions in dry eye patients with chronic GVHD (cGVHD) in a prospective comparative study. Thirty eyes of 15 patients refractory to baseline treatment were recruited and the patients assigned for topical Cys treatment group ...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1705900

    authors: Wang Y,Ogawa Y,Dogru M,Kawai M,Tatematsu Y,Uchino M,Okada N,Igarashi A,Kujira A,Fujishima H,Okamoto S,Shimazaki J,Tsubota K

    更新日期:2008-02-01 00:00:00

  • Evidence of alloreactive T lymphocytes in fetal liver: implications for fetal hematopoietic stem cell transplantation.

    abstract::The use of hematopoietic stem cells for in utero transplantation to create permanent hematochimerism represents a new concept in fetal therapy, although this approach has provided heterogeneous results. In this paper we have undertaken molecular, phenotypic and functional studies aimed at identifying the presence of f...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702108

    authors: Renda MC,Fecarotta E,Dieli F,Markling L,Westgren M,Damiani G,Jakil C,Picciotto F,Maggio A

    更新日期:2000-01-01 00:00:00

  • Conditioning with cyclophosphamide/antithymocyte globulin for allogeneic bone marrow transplantation from HLA-matched siblings in children with severe aplastic anemia.

    abstract::Graft rejection has been a problem after bone marrow transplantation for patients with severe aplastic anemia (SAA). Ten children with SAA were conditioned for bone marrow transplantation from HLA-identical siblings, using cyclophosphamide (CY, 50 mg/kg) plus antithymocyte globulin (ATG, 15 mg/kg) for 4 successive day...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1700795

    authors: Azuma E,Kojima S,Kato K,Matsuyama T,Yamada Y,Kondo N,Sawada H,Hanada M,Shibata T,Tabata N,Watanabe M,Shimono Y,Deguchi T,Umemoto M,Higashikawa M,Kawasaki H,Komada Y,Sakurai M

    更新日期:1997-06-01 00:00:00

  • Toxoplasma retinitis/encephalitis 9 months after allogeneic bone marrow transplantation.

    abstract::In a 34-year-old patient toxoplasma retinitis/encephalitis developed 9 months after bone marrow transplantation. The BMT was complicated with a serious GVHD. Although she initially responded well to antibiotic therapy she died 2 years after BMT due to progressive infection. ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701128

    authors: Brinkman K,Debast S,Sauerwein R,Ooyman F,Hiel J,Raemaekers J

    更新日期:1998-03-01 00:00:00

  • Hematopoietic SCT for the Black African and non-Black African variants of sickle cell anemia.

    abstract::Sickle cell anemia (SCA) remains associated with high risks of morbidity and early death. Allogeneic hematopoietic SCT (HSCT) is the only curative treatment for SCA. We report our experience with transplantation in a group of patients with the non-Black African variant and the Black African variant of SCA. This study ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2014.167

    authors: Lucarelli G,Isgrò A,Sodani P,Marziali M,Gaziev J,Paciaroni K,Gallucci C,Cardarelli L,Ribersani M,Alfieri C,De Angelis G,Armiento D,Andreani M,Testi M,Amato A,Akinyanju OO,Wakama TT

    更新日期:2014-11-01 00:00:00

  • CR represents an early index of potential long survival in multiple myeloma.

    abstract::To assess the impact of CR on survival in multiple myeloma. Retrospective evaluation of response and survival among 758 consecutive patients with multiple myeloma treated at a single center, of whom 395 patients received intensive therapy supported by autologous stem cells within the first year. Survival times were ca...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2009.176

    authors: Wang M,Delasalle K,Feng L,Thomas S,Giralt S,Qazilbash M,Handy B,Lee JJ,Alexanian R

    更新日期:2010-03-01 00:00:00

  • Risk factors and prognosis of hepatic acute GvHD after allogeneic hematopoietic cell transplantation.

    abstract::Hepatic acute GvHD (aGvHD) is associated with high mortality owing to poor response to immunosuppressive therapy. The pathogenesis of hepatic aGvHD differs from that of other lesions, and specific risk factors related to pre-transplant liver conditions should be determined. We conducted a cohort study by using a Japan...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/bmt.2015.205

    authors: Arai Y,Kanda J,Nakasone H,Kondo T,Uchida N,Fukuda T,Ohashi K,Kaida K,Iwato K,Eto T,Kanda Y,Nakamae H,Nagamura-Inoue T,Morishima Y,Hirokawa M,Atsuta Y,Murata M,GVHD working group of the Japan Society for Hematopoietic Ce

    更新日期:2016-01-01 00:00:00

  • The rationale behind autologous autoimmune hematopoietic stem cell transplant conditioning regimens: concerns over the use of total-body irradiation in systemic sclerosis.

    abstract::Hematopoietic stem cell transplantation (HSCT) is becoming an increasingly recognized indication for treatment of autoimmune diseases and severe immune-mediated disorders. However, multicenter registry data have demonstrated higher than anticipated early toxicity, approximately 10% for autoimmune diseases in general, ...

    journal_title:Bone marrow transplantation

    pub_type: 社论,评审

    doi:10.1038/sj.bmt.1704671

    authors: Burt RK,Patel D,Thomas J,Yeager A,Traynor A,Heipe F,Arnold R,Marmont A,Collier D,Glatstein E,Snowden J

    更新日期:2004-11-01 00:00:00

  • Successful second allogeneic peripheral blood stem cell transplantation and donor lymphocyte infusion in patients with relapsed acute leukemia using the same donors as for the initial allogeneic bone marrow transplantation.

    abstract::We report the successful treatment of two acute lympho- blastic leukemia (ALL) patients who relapsed following allogeneic bone marrow transplantation (allo-BMT) with allogeneic peripheral blood sem cell transplantation(allo-PBSCT) and donor lymphocyte infusion (DLI) from the same HLA-identical related donors as those ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704059

    authors: Ishikawa J,Maeda T,Kashiwagi H,Yoshida H,Takahashi I,Kawamoto SI,Yamada M,Kato H,Nishiura T,Tomiyama Y,Matsuzawa Y

    更新日期:2003-06-01 00:00:00

  • Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience.

    abstract::Relapse of chronic lymphocytic leukemia (CLL) after allogeneic hematopoietic cell transplantation (HCT) remains a clinical challenge. We studied in a phase II trial whether the addition of peri-transplant rituximab would reduce the relapse risk compared with historical controls (n = 157). Patients (n = 55) received fl...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-019-0660-8

    authors: Shadman M,Maloney DG,Storer B,Sandmaier BM,Chauncey TR,Smedegaard Andersen N,Niederwieser D,Shizuru J,Bruno B,Pulsipher MA,Maziarz RT,Agura ED,Hari P,Langston AA,Maris MB,McSweeney PA,Storb R,Sorror ML

    更新日期:2020-01-01 00:00:00

  • Influence of total nucleated cell dose from marrow harvests on outcome in patients with acute myelogenous leukemia undergoing autologous transplantation.

    abstract::This retrospective study was conducted to determine whether the total number of nucleated cells (TNC)/kg collected at marrow harvest was associated with outcome in 151 patients with acute myelogenous leukemia (AML) who received an autologous purged (n = 67) or non-purged (n = 84) marrow transplant. At the time of tran...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Demirer T,Gooley T,Buckner CD,Petersen FB,Lilleby K,Rowley S,Sanders J,Storb R,Appelbaum FR,Bensinger WI

    更新日期:1995-06-01 00:00:00

  • Autologous bone marrow transplantation for acute lymphoblastic leukemia.

    abstract::Between December 1979 and February 1991, 89 patients with ALL received autologous BMT. Median patient age was 18.4 years. Ten patients were in first remission, 52 were in second or greater remission and 27 were in relapse at the time of transplant. Conditioning regimens utilized chemotherapy alone (5 patients) or in c...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Doney K,Buckner CD,Fisher L,Petersen FB,Sanders J,Appelbaum FR,Anasetti C,Badger C,Bensinger W,Deeg HJ

    更新日期:1993-10-01 00:00:00

  • Tacrolimus pharmacokinetics in BMT patients.

    abstract::The pharmacokinetics of tacrolimus following its administration as monotherapy or in combination with corticosteroids or methotrexate to 31 BMT patients are presented. All patients received i.v. tacrolimus initially and were subsequently switched to p.o. dosing. Patients received methotrexate by i.v. bolus on post-tra...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1038/sj.bmt.1701054

    authors: Boswell GW,Bekersky I,Fay J,Wingard J,Antin J,Weisdorf D,Maher R,Fitzsimmons W,Nash R

    更新日期:1998-01-01 00:00:00

  • Monthly prospective analysis of hematopoietic chimerism after allogeneic hematopoietic cell transplantation.

    abstract:SUMMARY:Hematopoietic chimerism (HpC) was assayed monthly using a sensitive, polymerase chain reaction (PCR) -based method in consecutive patients. Between January 1998 and April 2002, 181 patients underwent non-T cell depleted allogeneic hematopoietic cell transplantation (HCT). A total of 163 patients were evaluable ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704147

    authors: Lee KH,Lee JH,Choi SJ,Lee JH,Kim S,Seol M,Lee YS,Kim WK,Kwon MR,Choi SJ,Park CJ,Chi HS,Lee JS

    更新日期:2003-08-01 00:00:00

  • Stem cell donor registry activities during the COVID-19 pandemic: a field report by DKMS.

    abstract::The COVID-19 pandemic has serious implications also for patients with other diseases. Here, we describe the effects of the pandemic on unrelated hematopoietic stem cell donation and transplantation from the perspective of DKMS, a large international donor registry. Especially, we cover the development of PBSC and bone...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-01138-0

    authors: Mengling T,Rall G,Bernas SN,Astreou N,Bochert S,Boelk T,Buk D,Burkard K,Endert D,Gnant K,Hildebrand S,Köksaldi H,Petit I,Sauter J,Seitz S,Stolze J,Weber K,Weber M,Lange V,Pingel J,Platz A,Schäfer T,Schetelig J

    更新日期:2020-11-20 00:00:00

  • Impact of different strategies of second-line stem cell harvest on the outcome of autologous transplantation in poor peripheral blood stem cell mobilizers.

    abstract::The optimal approach to obtain an adequate graft for transplantation in patients with poor peripheral blood stem cell (PBSC) mobilization remains unclear. We retrospectively assessed the impact of different strategies of second-line stem cell harvest on the transplantation outcome of patients who failed PBSC mobilizat...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705147

    authors: Goterris R,Hernández-Boluda JC,Teruel A,Gómez C,Lis MJ,Terol MJ,Tormo M,Solano C,Arbona C

    更新日期:2005-11-01 00:00:00

  • Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma.

    abstract::We present three patients with aggressive non-Hodgkin's B-cell lymphoma (NHL) who received anti-CD19 chimeric antigen receptor T (CAR T) cells therapy after failure of several lines of chemotherapy that developed pseudo-progression. One-week clinical and radiological findings were consistent with tumor progression. Po...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-01156-y

    authors: Danylesko I,Shouval R,Shem-Tov N,Yerushalmi R,Jacoby E,Besser MJ,Shimoni A,Davidson T,Beider K,Mevorach D,Fried S,Nagler A,Avigdor A

    更新日期:2020-12-03 00:00:00

  • Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.

    abstract::Relapse is a serious complication following high-dose therapy and autologous bone marrow transplantation (ABMT) for malignant lymphoma (ML). Allogeneic transplantation (alloSCT) is a therapeutic option. However, it is associated with a high incidence of transplant-related organ toxicity and mortality. We recently repo...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702392

    authors: Nagler A,Slavin S,Varadi G,Naparstek E,Samuel S,Or R

    更新日期:2000-05-01 00:00:00

  • Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results.

    abstract:SUMMARY:High-dose busulfan is an important component of myeloablative regimens. Variable drug exposure may occur following oral administration. Therefore, the use of intravenous busulfan has been advocated. Previous work has suggested a cumulative dosage of 16 mg/kg for haematopoietic transplantation in children less t...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704209

    authors: Dalle JH,Wall D,Theoret Y,Duval M,Shaw L,Larocque D,Taylor C,Gardiner J,Vachon MF,Champagne MA

    更新日期:2003-10-01 00:00:00

  • Cryotherapy in the prevention of oral mucositis in patients receiving low-dose methotrexate following myeloablative allogeneic stem cell transplantation: a prospective randomized study of the Gruppo Italiano Trapianto di Midollo Osseo nurses group.

    abstract::Severe oral mucositis is a major cause of morbidity following allogeneic hematopoietic stem cell transplantation (AHSCT). Cryotherapy, that is, the application of ice chips on the mucosa of the oral cavity during the administration of antineoplastic agents, may reduce the incidence and severity of chemotherapy-related...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1038/sj.bmt.1705590

    authors: Gori E,Arpinati M,Bonifazi F,Errico A,Mega A,Alberani F,Sabbi V,Costazza G,Leanza S,Borrelli C,Berni M,Feraut C,Polato E,Altieri MC,Pirola E,Loddo MC,Banfi M,Barzetti L,Calza S,Brignoli C,Bandini G,De Vivo A,B

    更新日期:2007-03-01 00:00:00

  • Collection of peripheral blood stem cells in multiple myeloma following single high-dose cyclophosphamide with and without recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF).

    abstract::High-dose cyclophosphamide (HD-CY; 7 g/m2) was administered to patients suffering from high risk multiple myeloma (MM). The safety of this procedure, the recirculation and collection of peripheral blood stem cells (PBSC) and the effect of rhGM-CSF and HD-CY were studied. Group I patients (n = 21) were treated with HD-...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:

    authors: Boiron JM,Marit G,Fabéres C,Cony-Makhoul P,Foures C,Ferrer AM,Cristol G,Sarrat A,Girault D,Reiffers J

    更新日期:1993-07-01 00:00:00

  • Consensus opinion on immune-mediated cytopenias after hematopoietic cell transplant for inherited metabolic disorders.

    abstract::Hematopoietic stem cell transplantation (HCT) has been increasingly used for patients with inherited metabolic disorders (IMD). Immune mediated cytopenias (IMCs) after HCT, manifesting as hemolytic anemia, thrombocytopenia, and/or neutropenia, are recognized as a significant complication in this patient population, ye...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/s41409-020-01179-5

    authors: Gupta AO,Jan Boelens J,Ebens CL,Kurtzberg J,Lund TC,Smith AR,Wagner JE,Wynn R,Blazar BR,Orchard PJ

    更新日期:2021-01-13 00:00:00

  • Standardized parenteral alanyl-glutamine dipeptide supplementation is not beneficial in autologous transplant patients: a randomized, double-blind, placebo controlled study.

    abstract::We conducted a controlled, double-blind study of parenteral glutamine supplementation in an unselected group of consecutive autologous transplant patients. Patients received 30 g of alanyl-glutamine dipeptide (Dipeptiven; Fresenius-Kabi, Bad Homburg, Germany) or glutamine-free amino acid solution i.v. from day +1 to d...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1038/sj.bmt.1703759

    authors: Pytlík R,Benes P,Patorková M,Chocenská E,Gregora E,Procházka B,Kozák T

    更新日期:2002-12-01 00:00:00

  • Cost-effectiveness of CD34+ dose in peripheral blood progenitor cell transplantation for non-Hodgkin's lymphoma patients: a single centre study.

    abstract::Intensive high-dose chemotherapy with peripheral blood progenitor cell (PBPC) transplantation is a common strategy for aggressive non-Hodgkin's lymphomas (NHL). A retrospective cost-effectiveness analysis of CD34+ cell dose was carried out. Between 1994 and 1998, 28 patients were included. Efficacy was measured by the...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702378

    authors: Limat S,Woronoff-Lemsi MC,Deconinck E,Racadot E,Jacquet M,Herve P,Cahn JY

    更新日期:2000-05-01 00:00:00

  • Natural killer cells as effector cells of graft-versus-leukemia activity in a murine transplantation model.

    abstract::The transfer of cytotoxic effector cells reduces the risk of relapse after allogeneic BMT. Two murine leukemia cell lines, A20 (B lymphocytic) and WEHI-3 (myelomonocytic), were used to investigate antileukemic effector mechanisms operating independently from graft-versus-host disease (GVHD). Different results were obt...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Uharek L,Glass B,Gaska T,Zeiss M,Gassmann W,Löffler H,Müller-Ruchholtz W

    更新日期:1993-01-01 00:00:00

  • Bone marrow transplantation in sickle cell disease: the Belgian experience.

    abstract::Twenty eight patients underwent bone marrow transplantation (BMT) for sickle cell anemia in Belgium. The patients were originating from Central Africa, were young and symptomatic. Engraftment occurred in all patients and was sustained in 25. In 3 patients, a bone marrow rejection was observed. One of these patients un...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Vermylen C,Cornu G,Ferster A,Ninane J,Sariban E

    更新日期:1993-01-01 00:00:00